Johnson & Johnson (JNJ– Receive a report Candidates for a single-shot vaccine were shown to be safe and able to produce meaningful immune responses in early trials, according to a report published Wednesday.
A single shot of the vaccine “delivers a sustained antibody,” J&J Chief Scientific Officer Dr. Paul Stoffels told CNBC. The results “assured” the vaccine was effective, Stoffels told CNBC.
The results of the Phase 1-2 trial were published on Wednesday. New England Journal of Medicine.
Candidates for the Johnson & Johnson vaccine are currently in Phase III trials to determine their true efficacy. Results from that study are expected later this month.
If successful and approved, the vaccine will become the third vaccine to combat the COVID-19 epidemic, which remains out of control in the United States and around the world.
Nearly 400,000 Americans have died from the disease, and more than 22 million infected.
Vaccine co-developed by Pfizer (PFE– Receive a report And BioNTech (BNTX– Receive a report It was approved for emergency use last month along with a second vaccine from Moderna. (MRNA– Receive a reportBoth need to be followed up with the booster shot and stored at very low temperatures, complicating the distribution and release of the vaccine. The United States is also significantly behind the projected vaccination schedule that calls for 20 million vaccinations by the end of December. Until now, there were only 10 million.
The Johnson & Johnson vaccine requires only one injection and can be stored at higher temperatures. However, the launch will go on as well, and it will likely not begin in earnest until April due to production delays, assuming the FDA has been cleared for use.
Johnson and Johnson’s shares rose 1.08 percent to $ 159.60 in after-hours trading Wednesday.